Your shopping cart is currently empty

20S Proteasome activator 1 is a 20S proteasome activator with IC50 values of 0.3 μM for trypsin-like sites, 0.7 μM for chymotrypsin-like sites, and 1.8 μM for caspase sites. It prevents the accumulation of pathogenic alpha-synuclein (A53T) mutants through translation in the cellular system, thereby reducing the probability of disease occurrence. 20S Proteasome activator 1 can be used to study neurodegenerative diseases.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $64 | In Stock | In Stock | |
| 10 mg | $98 | In Stock | In Stock | |
| 25 mg | $192 | In Stock | In Stock | |
| 50 mg | $328 | In Stock | In Stock | |
| 100 mg | $538 | - | In Stock |
| Description | 20S Proteasome activator 1 is a 20S proteasome activator with IC50 values of 0.3 μM for trypsin-like sites, 0.7 μM for chymotrypsin-like sites, and 1.8 μM for caspase sites. It prevents the accumulation of pathogenic alpha-synuclein (A53T) mutants through translation in the cellular system, thereby reducing the probability of disease occurrence. 20S Proteasome activator 1 can be used to study neurodegenerative diseases. |
| Targets&IC50 | Trypsin like site:0.3 μM, Chymotrypsin-like site:0.7 μM, Caspase-like site:1.8 μM |
| In vitro | At concentrations of 2.5-15 μM and a treatment duration of 45 minutes, 20S Proteasome activator 1 (compound 19) degrades 73% of α-synuclein at 10 μM and over 80% at 15 μM.[1] At concentrations of 5-15 μM and a 24-hour treatment period, 20S Proteasome activator 1 reduces A53T mutant α-synuclein by 25%. It also exhibits a dose-dependent reduction in the augmentation of α-synuclein in Hek-293T cells transiently transfected with an A53T mutant α-synuclein plasmid, achieving a 67% decrease at 15 μM.[1] |
| Molecular Weight | 492.97 |
| Formula | C27H19ClF2N2OS |
| Cas No. | 2761578-18-9 |
| Smiles | C(CC(N(C1=CC=C(F)C=C1)C2=CC=C(F)C=C2)=O)N3C=4C(SC=5C3=CC=CC5)=CC=C(Cl)C4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (507.13 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 2.5 mg/mL (5.07 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.